Tuesday

Trial Tuesday: Wisdom Of The Masses

Daraxonrasib doubles survival in pancreatic cancer, BMS puts numbers behind its CELMoD bet, and the trial count quietly falls again.

Jun 2, 2026 Manas Mishra 8 min read members

Trial Tuesday: China's ASCO Moment

For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.

May 26, 2026 Manas Mishra 13 min read members

Trial Tuesday: The data almost cooperated. Almost.

Here is a thought experiment: where would we be if the FDA and other regulators did not allow trial flexibility?

May 19, 2026 Manas Mishra 10 min read members

Page 1 of 1

Trial Tuesday: Wisdom Of The Masses

Trial Tuesday: China's ASCO Moment

Trial Tuesday: The data almost cooperated. Almost.